Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - Flinders Clinical Trial Services Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, was introduced to regulate the quality, safety, and efficacy of therapeutic goods within Australia. The Act provides the legal framework for the regulation of therapeutic goods, including medicines, medical devices, and blood products, to ensure that they are safe for consumers and health professionals to use. One of the key mechanisms provided by the Act is the issuance of licences to manufacturers, which is designed to maintain and enforce high standards in the production and supply of therapeutic goods. The Act aims to protect public health by ensuring that only therapeutic goods that meet the required standards are available for use. The publication of the list of manufacturers granted licences is a critical aspect of this regulatory framework, enabling transparency and accountability in the manufacturing of therapeutic goods. The Therapeutic Goods Administration (TGA), as part of the Department of Health, is responsible for the administration and enforcement of the Therapeutic Goods Act 1989. The policy objective of the Act, as highlighted in the legislative text, is to safeguard public health by ensuring that therapeutic goods are of high quality, safe, and effective for their intended use. This is achieved by licensing manufacturers and requiring them to comply with stringent manufacturing standards. The publication of the list of licensed manufacturers, such as Flinders Clinical Trial Services Pty Ltd, serves to inform the public and industry stakeholders about the entities authorised to produce therapeutic goods, thereby reinforcing the regulatory oversight and maintaining public confidence in the safety and quality of these products.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities and individuals involved in the manufacture, supply, importation, or advertisement of therapeutic goods in Australia. The Act encompasses a broad range of therapeutic goods, including medicines, medical devices, blood and blood components, tissues, and human cells, ensuring that they meet safety, quality, and efficacy standards. The application of the Act is national, covering the entire Commonwealth of Australia, and it includes territories. Flinders Clinical Trial Services Pty Ltd, a company granted a licence under Section 38 of the Act, is an example of an entity regulated by this legislation. The licence ensures that the company is authorised to manufacture therapeutic goods, which must comply with stringent regulatory requirements. The Act provides for the exclusion of certain goods or classes of goods through subordinate instruments, but the primary legislation itself does not specify detailed exclusions. The geographic jurisdiction of the Therapeutic Goods Act is comprehensive, applying uniformly across all states and territories within Australia.

Key Provisions

The Therapeutic Goods Act 1989, under Section 38, facilitates the grant of licences for the manufacture of therapeutic goods. Specifically, Section 38 allows the Secretary of the Department of Health to issue such licences. The Gazette C2015G00833, issued by Hongxia Jin, a Delegate of the Secretary of the Department of Health, provides the details of the licence granted to Flinders Clinical Trial Services Pty Ltd, a company located at 15 Lum Street, Export Park, SA, 5950. This licence, identified as mi-2014-li-11373-1, authorises the company to manufacture therapeutic goods. The Therapeutic Goods Act 1989 imposes various obligations on the entities it governs, including the requirement for manufacturers of therapeutic goods to hold a valid licence. Flinders Clinical Trial Services Pty Ltd, having been granted Licence No. mi-2014-li-11373-1, is required to comply with all provisions of the Act. This includes adhering to manufacturing standards, ensuring quality control, and maintaining records as specified by the Act. These obligations are critical to safeguarding public health and ensuring that therapeutic goods meet the necessary safety, efficacy, and quality standards. Breaches of the Therapeutic Goods Act 1989 can lead to significant consequences, including both criminal and civil penalties. Under the Act, unauthorised manufacture of therapeutic goods is an offence, and penalties can be severe. For example, individuals or entities found guilty of manufacturing therapeutic goods without a valid licence may face fines and imprisonment. The maximum penalties can vary depending on the severity of the breach, but they are designed to deter non-compliance and protect public health. Additionally, the Act allows for the suspension or revocation of a licence if the holder fails to comply with the regulatory requirements. This ensures that only entities meeting the stringent standards set by the Act can continue to operate in the therapeutic goods manufacturing sector.